-
Something wrong with this record ?
Amblyopia treatment of adults with dichoptic training using the virtual reality oculus rift head mounted display: preliminary results
P. Žiak, A. Holm, J. Halička, P. Mojžiš, DP. Piñero,
Language English Country Great Britain
Document type Journal Article
NLK
BioMedCentral
from 2001-12-01
BioMedCentral Open Access
from 2001
Directory of Open Access Journals
from 2001
Free Medical Journals
from 2001
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2001-04-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Medline Complete (EBSCOhost)
from 2001-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
Springer Nature OA/Free Journals
from 2001-12-01
- MeSH
- Amblyopia physiopathology therapy MeSH
- Time Factors MeSH
- Perceptual Distortion physiology MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Follow-Up Studies MeSH
- Surveys and Questionnaires MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Sensory Deprivation MeSH
- Virtual Reality Exposure Therapy methods MeSH
- Vision, Binocular physiology MeSH
- Treatment Outcome MeSH
- Imaging, Three-Dimensional * MeSH
- Visual Acuity * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The gold standard treatments in amblyopia are penalizing therapies, such as patching or blurring vision with atropine that are aimed at forcing the use of the amblyopic eye. However, in the last years, new therapies are being developed and validated, such as dichoptic visual training, aimed at stimulating the amblyopic eye and eliminating the interocular supression. PURPOSE: To evaluate the effect of dichoptic visual training using a virtual reality head mounted display in a sample of anisometropic amblyopic adults and to evaluate the potential usefulness of this option of treatment. METHODS: A total of 17 subjects (10 men, 7 women) with a mean age of 31.2 years (range, 17-69 year) and anisometropic amblyopia were enrolled. Best corrected visual acuity (BCVA) and stereoacuity (Stereo Randot graded circle test) changes were evaluated after 8 sessions (40 min per session) of dichoptic training with the computer game Diplopia Game (Vivid Vision) run in the Oculus Rift OC DK2 virtual reality head mounted display (Oculus VR). RESULTS: Mean BCVA in amblyopic eye improved significantly from a logMAR value of 0.58 ± 0.35 before training to a post-training value of 0.43 ± 0.38 (p < 0.01). Forty-seven percent of the participants achieved BCVA of 20/40 or better after the training as compared to 30% before the training. Mean stereoacuity changed from a value of 263.3 ± 135.1 before dichoptic training to a value of 176.7 ± 152.4 s of arc after training (p < 0.01). A total of 8 patients (47.1%) before dichoptic treatment had unmeasurable stereoacuity while this only occurred in 2 patients (11.8%) after training. CONCLUSIONS: Dichoptic training using a virtual reality head mounted display seems to be an effective option of treatment in adults with anisometropic amblyopia. Future clinical trials are needed to confirm this preliminary evidence. TRIAL REGISTRATION: Trial ID: ISRCTN62086471 . Date registered: 13/06/2017. Retrospectively registered.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016514
- 003
- CZ-PrNML
- 005
- 20180517093811.0
- 007
- ta
- 008
- 180515s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12886-017-0501-8 $2 doi
- 035 __
- $a (PubMed)28659140
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Žiak, Peter $u Eye clinic, Jessenius faculty of Medicine in Martin, Commenius University in Bratislava, Bratislava, Slovakia. 1ziakpeter@gmail.com. UVEA Mediklinik, Martin, Slovakia. 1ziakpeter@gmail.com.
- 245 10
- $a Amblyopia treatment of adults with dichoptic training using the virtual reality oculus rift head mounted display: preliminary results / $c P. Žiak, A. Holm, J. Halička, P. Mojžiš, DP. Piñero,
- 520 9_
- $a BACKGROUND: The gold standard treatments in amblyopia are penalizing therapies, such as patching or blurring vision with atropine that are aimed at forcing the use of the amblyopic eye. However, in the last years, new therapies are being developed and validated, such as dichoptic visual training, aimed at stimulating the amblyopic eye and eliminating the interocular supression. PURPOSE: To evaluate the effect of dichoptic visual training using a virtual reality head mounted display in a sample of anisometropic amblyopic adults and to evaluate the potential usefulness of this option of treatment. METHODS: A total of 17 subjects (10 men, 7 women) with a mean age of 31.2 years (range, 17-69 year) and anisometropic amblyopia were enrolled. Best corrected visual acuity (BCVA) and stereoacuity (Stereo Randot graded circle test) changes were evaluated after 8 sessions (40 min per session) of dichoptic training with the computer game Diplopia Game (Vivid Vision) run in the Oculus Rift OC DK2 virtual reality head mounted display (Oculus VR). RESULTS: Mean BCVA in amblyopic eye improved significantly from a logMAR value of 0.58 ± 0.35 before training to a post-training value of 0.43 ± 0.38 (p < 0.01). Forty-seven percent of the participants achieved BCVA of 20/40 or better after the training as compared to 30% before the training. Mean stereoacuity changed from a value of 263.3 ± 135.1 before dichoptic training to a value of 176.7 ± 152.4 s of arc after training (p < 0.01). A total of 8 patients (47.1%) before dichoptic treatment had unmeasurable stereoacuity while this only occurred in 2 patients (11.8%) after training. CONCLUSIONS: Dichoptic training using a virtual reality head mounted display seems to be an effective option of treatment in adults with anisometropic amblyopia. Future clinical trials are needed to confirm this preliminary evidence. TRIAL REGISTRATION: Trial ID: ISRCTN62086471 . Date registered: 13/06/2017. Retrospectively registered.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a amblyopie $x patofyziologie $x terapie $7 D000550
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a zobrazování trojrozměrné $7 D021621
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a deformace percepce $x fyziologie $7 D010469
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a senzorická deprivace $7 D012683
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a terapie pomocí virtuální reality $x metody $7 D063367
- 650 _2
- $a vidění binokulární $x fyziologie $7 D015348
- 650 12
- $a zraková ostrost $7 D014792
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Holm, Anders $u Eye clinic, Jessenius faculty of Medicine in Martin, Commenius University in Bratislava, Bratislava, Slovakia. UVEA Mediklinik, Martin, Slovakia.
- 700 1_
- $a Halička, Juraj $u Eye clinic, Jessenius faculty of Medicine in Martin, Commenius University in Bratislava, Bratislava, Slovakia. UVEA Mediklinik, Martin, Slovakia.
- 700 1_
- $a Mojžiš, Peter $u Premium Clinic, Teplice, Czech Republic.
- 700 1_
- $a Piñero, David P $u Department of Optics, Pharmacology and Anatomy, University of Alicante, Alicante, Spain.
- 773 0_
- $w MED00008199 $t BMC ophthalmology $x 1471-2415 $g Roč. 17, č. 1 (2017), s. 105
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28659140 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180517093947 $b ABA008
- 999 __
- $a ok $b bmc $g 1300138 $s 1013354
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 17 $c 1 $d 105 $e 20170628 $i 1471-2415 $m BMC ophthalmology $n BMC Ophthalmol $x MED00008199
- LZP __
- $a Pubmed-20180515